This Article Full Text (OnlineFirst PDF) All Versions of this Article: 1087057108319738v1 13/6/468    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Keller, P. M. Articles by Schwartz, B. Search for Related Content PubMed PubMed Citation Articles by Keller, P. M. Articles by Schwartz, B. Social Bookmarking                         What's this?

A High-Throughput Screen for Endothelial Lipase Using HDL as Substrate

GlaxoSmithKline Pharmaceuticals

^* To whom correspondence should be addressed. E-mail: Benjamin_2_Schwartz{at}gsk.com.

	Abstract

Endothelial lipase (EL) is a 482-amino-acid protein from the triglyceride lipase gene family that uses a Ser-His-Asp triad for catalysis. Its expression in endothelial cells and preference for phospholipids rather than triglycerides are unique. Animal models in which it is overexpressed or knocked out indicate EL levels are inversely correlated with high-density lipoprotein cholesterol (HDL-C). HDL-C is commonly referred to as the good form of cholesterol because it is involved in the reverse cholesterol transport pathway, in which excess cholesterol is effluxed from peripheral tissues for excretion or reabsorption. Thus, EL inhibition in humans is expected to lead to increases in HDL levels and possibly a decrease in cardiovascular disease. To discover inhibitors of EL, a coupled assay for EL has been developed, using its native substrate, HDL. Hydrolysis of HDL by EL yields free fatty acids, which are coupled through acyl-CoA synthetase, acyl-CoA oxidase, and horseradish peroxidase to produce the fluorescent species resorufin. This assay was developed into a 5-µL, 1536-well assay format, and a high-throughput screen was executed against the GSK collection. In addition to describing the screening results, novel post-HTS mechanism-of-action studies were developed for EL and applied to 1 of the screening hits as an example. (Journal of Biomolecular Screening XXXX:xx-xx)

First published on June 19, 2008, doi:10.1177/1087057108319738

Journal of Biomolecular Screening 2008;13:468.

A more recent version of this article appeared on July 1, 2008


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?